Skip to content

Behavioral effects of orally administered glycine in socially housed monkeys chronically treated with phencyclidine.

Gary S Linn, Robert T O'Keeffe, Kenneth Lifshitz, Charles Schroeder, Daniel C Javitt

Psychopharmacology May 1, 2007 DOI: 10.1007/s00213-007-0771-6 via PubMed

Summary

AI-generated from the abstract

Glycine treatment reversed the effects of the dissociative anesthetic PCP on stereotyped pacing in socially housed monkeys but had no effect on scanning behavior. Chronic PCP infusion in ten monkeys produced behavioral symptoms modeling both positive and negative symptoms of schizophrenia. Eight of ten animals experienced extreme motoric and physiological episodes during stressful events. The results suggest glycine may be beneficial for negative symptoms of schizophrenia, and that chronic PCP in primates could serve as a model for developing drugs targeting schizophrenia symptoms.

Study at a glance

Characteristics Controlled before-after study Peer reviewed
Sample size 10
Population Socially housed monkeys
Intervention Glycine
Dose 2 g kg(-1) day(-1) bid p.o.
Key finding Glycine treatment significantly reversed PCP-induced stereotyped pacing but had no effect on scanning behavior in primates.

Abstract

Schizophrenia is a major mental disorder. Dissociative anesthetics such as phencyclidine (PCP) produce a syndrome in humans that is clinically indistinguishable from schizophrenia by blocking neurotransmission at N-methyl-D-aspartate (NMDA)-type glutamate receptors. NMDA receptors in brain are modulated by the amino acid glycine (GLY), which reverses neurochemical and behavioral effects of PCP in rodents. The present study investigates GLY effects on PCP-induced behavior in primates. In primates, PCP induces characteristic behavioral symptoms that can be used to model positive and negative symptoms of schizophrenia. This study investigated the effects of GLY treatment in ten socially housed monkeys receiving chronically infused PCP. Ten monkeys received escalating then stable doses of continuously infused PCP through a series of subcutaneously implanted osmotic minipumps. During a segment of the highest PCP dose period, monkeys were concurrently treated with glycine (2 g kg(-1) day(-1) bid p.o.). Behavioral observations were recorded during baseline and treatment periods. Chronic PCP treatment was associated with a progressive decrease in stereotyped pacing and a progressive increase in scanning behavior. Eight of ten animals had one or more episodes of extreme motoric and physiological responses precipitated by stressful events. GLY treatment significantly reversed the effects of PCP on stereotyped pacing but had no effect on scanning. The results support GLY treatment as beneficial for negative symptoms of schizophrenia. Although further validation is needed, the results also indicate that chronic PCP in primates may be an appropriate model system for development of drugs targeting positive and negative symptoms of schizophrenia.

Comments

No comments yet.

Log in to comment